台灣臨床試驗主持人資料庫|TPIDB

2017-08-15 - 2023-11-30

Phase III

Completed

A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1

Condition/Disease

Active Psoriatic Arthritis
Test Drug

ABT-494

Participate Sites
7Sites

Terminated6Sites

賴建志

Taipei Veterans General Hospital

Division of Rheumatology

郭昶甫

Linkou Chang Gung Medical Foundation

Division of Rheumatology

2016-12-13 - 2022-05-05

Phase III

Completed

Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)

Condition/Disease

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Test Drug

Venetoclax (ABT-199, GDC-0199)

Participate Sites
4Sites

Terminated3Sites

蕭樑材

Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-10-24 - 2021-03-08

Phase III

Not yet recruiting

Condition/Disease
Test Drug

Participate Sites
4Sites

Terminated1Sites

李重賓

Taipei Veterans General Hospital

Division of Others-

2018-02-14 - 2022-12-31

Phase I/II

Completed

A Phase I/II study to determine the maximum tolerated dose (MTD) and to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of antroquinonol in combination with nab-paclitaxel and gemcitabine in first line metastatic pancreatic cancer.

Condition/Disease

Pancreatic Neoplasm
Test Drug

Hocena

Participate Sites
2Sites

Recruiting2Sites

李重賓

Taipei Veterans General Hospital

Division of Hematology & Oncology

沈延盛

National Taiwan University Hospital

Division of General Surgery

2018-11-16 - 2023-09-30

Phase II

Completed

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Condition/Disease

Advanced Non-Small Cell Lung Cancer
Test Drug

MK-3475

Participate Sites
5Sites

Recruiting5Sites

羅永鴻

Taipei Veterans General Hospital

Division of Thoracic Medicine

2018-06-11 - 2023-01-31

Phase III

Completed

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer

Condition/Disease

Advanced Endometrial Cancer
Test Drug

Keytruda/Lenvima

Participate Sites
7Sites

Terminated7Sites

王鵬惠

Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2016-09-01 - 2020-12-31

Phase III

Completed

A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma

Condition/Disease

Advanced or Metastatic Urothelial Carcinoma
Test Drug

Pembrolizumab (MK-3475)/Keytruda

Participate Sites
5Sites

Terminated5Sites

黃逸修

Taipei Veterans General Hospital

Division of Urology

2018-09-01 - 2024-12-19

Phase III

Completed

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

Condition/Disease

Persistent, Recurrent, or Metastatic Cervical Cancer
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
6Sites

Recruiting1Sites

Terminated5Sites

王鵬惠

Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2023-02-15 - 2026-12-30

Phase I

Active

Condition/Disease
Test Drug

Participate Sites
1Sites

Recruiting1Sites

黃少嵩

Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2017-11-01 - 2021-05-20

Phase III

Completed

A Randomized, Open-label, Multi-center Phase 3 study to Compare the efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in patients with Unresectable Hepatocellular Carcinoma

Condition/Disease

unresectable HCC
Test Drug

Tislelizumab

Participate Sites
11Sites

Terminated9Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

Search Result

List